Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $212M
Founded date: 2020
Investors 4
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| 08.11.2023 | ARCH Ventu... | archventur... |
| - | DC Investm... | dcinvestme... |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.10.2024 | - | $82M | - |
| 18.04.2022 | - | $130M | - |
Mentions in press and media 5
| Date | Title | Description |
| 15.01.2025 | Be Bio Closes $92M Series C Financing | Be Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding. The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 23.10.2024 | Be Biopharma Raises $82M in Financing | Be Biopharma, a Cambridge, MA-based company which specializes in the discovery and development of engineered B Cell Medicines (BCMs), raised $82M in funding. Backers included ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta... |
| 18.04.2022 | Be Biopharma Closes $130M Financing | Be Biopharma, a Cambridge, MA-based developer of Engineered B Cell Medicines (BeCM), closed a $130m financing. The round, which brought total investment to over $180m, was led by ARCH Venture Partners with participation from Bristol Myers S... |
| - | Be Biopharma | “Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.” |